EGFR splicing variants in glioblastoma include EGFRvI (N-terminal deletion), EGFRvII (deletion of exons 14–15), EGFRvIII (in-frame deletion of exons 2–7), EGFRvIV (deletion of exons 25–27), and EGFRvV (deletion of exons 25–58); of these, EGFRvII and EGFRvIII have been confirmed to be constitutively active and oncogenic [17]. This evidence concerns the gene EGFR and glioblastoma.